
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by OmniSeq Staff | Feb 1, 2019

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
by OmniSeq Staff | Jan 24, 2019

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by Christina Black | May 9, 2018
...Follow Us on Twitter
This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today: https://bit.ly/3NAKg3S
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine